EA201892726A1 - Дейтерированный палбоциклиб - Google Patents

Дейтерированный палбоциклиб

Info

Publication number
EA201892726A1
EA201892726A1 EA201892726A EA201892726A EA201892726A1 EA 201892726 A1 EA201892726 A1 EA 201892726A1 EA 201892726 A EA201892726 A EA 201892726A EA 201892726 A EA201892726 A EA 201892726A EA 201892726 A1 EA201892726 A1 EA 201892726A1
Authority
EA
Eurasian Patent Office
Prior art keywords
present
deutered
palbocyclib
cdk
compositions
Prior art date
Application number
EA201892726A
Other languages
English (en)
Inventor
Адам Дж. Морган
Original Assignee
Консерт Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Консерт Фармасьютикалс, Инк. filed Critical Консерт Фармасьютикалс, Инк.
Publication of EA201892726A1 publication Critical patent/EA201892726A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/062—Organo-phosphoranes without P-C bonds

Abstract

Настоящее изобретение относится к новым пиридо[2,3-d]пиримидинонам и их фармацевтически приемлемым солям. Настоящее изобретение также относится к композициям, содержащим соединение согласно настоящему изобретению, и применению таких композиций в способах лечения заболеваний и состояний, которые успешно лечатся путем введения ингибитора CDK-4 и/или CDK-6.
EA201892726A 2013-03-15 2014-03-12 Дейтерированный палбоциклиб EA201892726A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361787540P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
EA201892726A1 true EA201892726A1 (ru) 2019-04-30

Family

ID=51581623

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201892726A EA201892726A1 (ru) 2013-03-15 2014-03-12 Дейтерированный палбоциклиб
EA201591628A EA032094B1 (ru) 2013-03-15 2014-03-12 Дейтерированный палбоциклиб

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201591628A EA032094B1 (ru) 2013-03-15 2014-03-12 Дейтерированный палбоциклиб

Country Status (8)

Country Link
US (3) US20160024084A1 (ru)
EP (2) EP2970209B1 (ru)
JP (1) JP2016512831A (ru)
AU (1) AU2014235462C1 (ru)
CA (1) CA2904054A1 (ru)
EA (2) EA201892726A1 (ru)
MX (1) MX2015012741A (ru)
WO (1) WO2014150925A2 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2954189A1 (en) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
CN105111201B (zh) * 2014-10-16 2017-01-11 上海页岩科技有限公司 5-甲基-2-(吡啶-2-基氨基)-8H-吡啶并[2,3-d]嘧啶-7-酮化合物
WO2016092442A1 (en) * 2014-12-08 2016-06-16 Sun Pharmaceutical Industries Limited Processes for the preparation of crystalline forms of palbociclib acetate
CN104892604B (zh) * 2015-06-19 2016-08-24 北京康立生医药技术开发有限公司 一种cdk4抑制剂的合成方法
CN105153149B (zh) * 2015-07-29 2017-09-19 江苏中邦制药有限公司 一种选择性激酶抑制剂Palbociclib的制备方法
EP3386981B1 (en) * 2015-12-13 2021-10-13 Hangzhou Innogate Pharma Co., Ltd. Heterocycles useful as anti-cancer agents
CN106986871B (zh) * 2017-03-29 2019-02-26 浙江同源康医药股份有限公司 一种氘代Palbociclib的晶型及其制备方法和应用
CN106967064B (zh) * 2017-03-29 2018-03-23 郑州泰基鸿诺医药股份有限公司 氘代Palbociclib的衍生物、制备方法及其应用
US20220024916A1 (en) * 2018-12-07 2022-01-27 Hangzhou Innogate Pharma Co., Ltd. Heterocyclic comipound as cdk-hdac dual pathway inhibitor
WO2021113595A1 (en) * 2019-12-06 2021-06-10 Beta Pharma, Inc. Phosphorus derivatives as kras inhibitors
LV15575A (lv) 2019-12-20 2021-06-20 Latvijas Organiskās Sintēzes Institūts Selenofēnhromēnu deiterēti analogi, to iegūšana un izmantošana

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
TW354293B (en) 1995-06-06 1999-03-11 Bristol Myers Squibb Co Prodrugs of paclitaxel derivatives
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
JP4101661B2 (ja) 2001-05-03 2008-06-18 エフ．ホフマン−ラ ロシュ アーゲー 非晶質メシル酸ネルフィナビルの製薬剤形
JP2005503425A (ja) 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
WO2003062236A1 (en) * 2002-01-22 2003-07-31 Warner-Lambert Company Llc 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES
EP1648889B1 (en) * 2003-07-11 2008-10-29 Warner-Lambert Company LLC Isethionate salt of a selective cdk4 inhibitor
CA2581169A1 (en) 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
WO2007050732A1 (en) 2005-10-28 2007-05-03 Abbott Laboratories INDAZOLE DERIVATIVES THAT INHIBIT TRPVl RECEPTOR
AU2007297286A1 (en) * 2006-09-08 2008-03-20 Pfizer Products Inc. Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
EP2109450A2 (en) 2006-12-14 2009-10-21 Panacea Pharmaceuticals, Inc. Methods of neuroprotection by cyclin-dependent kinase inhibition
US20090030005A1 (en) 2007-07-19 2009-01-29 Amgen Inc. Combinations for the treatment of cancer
US9259399B2 (en) 2007-11-07 2016-02-16 Cornell University Targeting CDK4 and CDK6 in cancer therapy
EP2242493B1 (en) * 2008-01-22 2013-06-05 Concert Pharmaceuticals Inc. Derivatives of gefitinib
JP2012504646A (ja) 2008-10-01 2012-02-23 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 選択的サイクリン依存性キナーゼ４／６阻害剤を用いた化学療法化合物に対する造血系の防護
JP2012504645A (ja) 2008-10-01 2012-02-23 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 健康な細胞に対する電離放射線の影響を低下させる又は防止するための医薬組成物
JP2012526850A (ja) 2009-05-13 2012-11-01 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル サイクリン依存性キナーゼ阻害剤及びその用法
UY33226A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
JP5918214B2 (ja) 2010-04-13 2016-05-18 ノバルティス アーゲー がんを治療するためのサイクリン依存性キナーゼ４またはサイクリン依存性キナーゼ（ｃｄｋ４／６）阻害剤およびｍｔｏｒ阻害剤を含む組合せ
CN101948467B (zh) * 2010-05-17 2012-07-25 苏州波锐生物医药科技有限公司 噻唑酰胺类化合物及其在制备抗恶性肿瘤药物中的用途
WO2012068381A2 (en) 2010-11-17 2012-05-24 The University Of North Carolina At Chapel Hill Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6

Also Published As

Publication number Publication date
JP2016512831A (ja) 2016-05-09
EP2970209B1 (en) 2018-12-26
AU2014235462A1 (en) 2015-09-17
EA032094B1 (ru) 2019-04-30
WO2014150925A2 (en) 2014-09-25
US20190225605A1 (en) 2019-07-25
AU2014235462C1 (en) 2018-11-01
AU2014235462B2 (en) 2018-05-17
EP2970209A2 (en) 2016-01-20
US20160024084A1 (en) 2016-01-28
EP2970209A4 (en) 2016-08-31
EA201591628A1 (ru) 2016-03-31
CA2904054A1 (en) 2014-09-25
EP3492470A1 (en) 2019-06-05
WO2014150925A3 (en) 2014-12-04
US20180051022A1 (en) 2018-02-22
MX2015012741A (es) 2016-02-19

Similar Documents

Publication Publication Date Title
EA201892726A1 (ru) Дейтерированный палбоциклиб
CY1122266T1 (el) Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
TR201901886T4 (tr) DNA-PK inhibitörleri.
PH12016500024A1 (en) Bromodomain inhibitor
MD4666B1 (ru) Ингибиторы Syk
UA117830C2 (uk) Похідні біпіразолу як інгібітори jak
EA201690094A1 (ru) Ингибиторы syk
EA201691070A1 (ru) Новые трициклические соединения в качестве противораковых средств
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
EA201690844A1 (ru) Ингибиторы gsk-3
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
MD20170011A2 (ru) Имидазопиридазиновые соединения
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
EA201790830A1 (ru) Ингибиторы альдостеронсинтазы
EA201790253A1 (ru) Ингибиторы альдостеронсинтазы
EA201591434A1 (ru) Способ обеспечения глазной нейропротекции
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
EA201590656A1 (ru) Азаиндолины
EA201600002A1 (ru) Производные пролекарства замещенных триазолопиридинов
EA201491878A1 (ru) Замещенные ксантиновые производные